Zymeworks Inc. (ZYME)

Redmile Group sold 3,214,096 ZYME shares, estimated at $70.10 million based on quarterly average prices. Meanwhile, the quarter-end value of the Zymeworks stake decreased by $50.35 million, reflecting both stock sales and price changes.

Zomedica (OTC: ZOMDF - Get Free Report) and Zymeworks (NYSE: ZYME - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Insider and Institutional Ownership 8.9% of Zomedica shares are

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET).

Zymeworks (NASDAQ: ZYME - Get Free Report) and Generex Biotechnology (OTCMKTS:GNBT - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk. Earnings and Valuation This table compares Zymeworks and

VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2026 Virtual Oncology Leadership Summit: Zymeworks' management will participate in one-on-one meetings February 18-19, 2026 virtually. TD Cowen 46th Annual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on March 2, 2026 at 14:30 pm – 15:00 pm Eastern Time (ET) in Boston, MA.

Zymeworks Inc. (NYSE: ZYME - Get Free Report) COO Mark Hollywood sold 6,120 shares of the company's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $138,740.40. Following the completion of the sale, the chief operating officer directly owned 132,913

Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company's corporate strategy announced in November.

Zymeworks delivered strong Phase 3 HERIZON-GEA-01 results for Ziihera, achieving over two years median overall survival in HER2-positive GEA. ZYME stands to receive up to $440 million in milestone payments upon regulatory approvals, dwarfing its recent $27.6 million quarterly revenue. Ziihera's efficacy was consistent across PD-L1 subgroups, with manageable safety, positioning it as a potential new first-line standard for HER2-positive GEA.

VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders.

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.

Zymeworks Inc. (NYSE: ZYME - Get Free Report) has been given a consensus recommendation of "Buy" by the eleven ratings firms that are covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the

VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.

Zymeworks Inc. (NYSE: ZYME - Get Free Report) insider Paul Andrew Moore sold 20,110 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $504,761.00. Following the transaction, the insider owned 31,212 shares of the company's stock, valued at

Zymeworks Inc. (NYSE: ZYME - Get Free Report) EVP Jeffrey Smith sold 10,538 shares of the company's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, for a total transaction of $264,503.80. Following the completion of the transaction, the executive vice president owned 18,352 shares of the

Assenagon Asset Management S.A. raised its stake in Zymeworks Inc. (NYSE: ZYME) by 169.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,326,774 shares of the company's stock after buying an additional 833,994 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.77% of